Concepedia

Author

Anu Thummala

Comprehensive Cancer Centers of Nevada

Also Known As

Anu R Thummala, Anu R. Thummala, Anu Thummala

22

Publications

2.3K

Citations

6

H-Index

14

Concepts

All Affiliations

Comprehensive Cancer Centers of NevadaJohannes Gutenberg University MainzSzent János KórházPetz Aladár Megyei Oktató KórházPfizer (United States)
AT

About

Anu Thummala is an author at Comprehensive Cancer Centers of Nevada specializing in cancer therapeutics, breast cancer, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

2.1K

2

Pharmacology

3

3

2K

3

Health Sciences

1

1

111

4

Pathology

1

1

67

5

Cancer Cell Biology

1

1

51

Anu Thummala

×

6

Publications

2.3K

Citations

6

H-Index

YearCitations

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng,

The Lancet Oncology

2014

1.9K

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Richard S. Finn, Katalin Boér, Igor Bondarenko,

Breast Cancer Research and Treatment

2020

164

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

Antoinette R. Tan, Gail S. Wright, Anu Thummala,

The Lancet Oncology

2019

111

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

Richard S. Finn, John Crown, István Láng,

Journal of Clinical Oncology

2017

67

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

Richard S. Finn, John Crown, István Láng,

Cancer Research

2014

51

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala,

Clinical Cancer Research

2021

39

Page 1